TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04033016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online social media intervention
Description: Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online social media intervention
Description: Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
Study: NCT03710161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D taken in two different dosages daily for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D taken in two different dosages daily for six months.
Study: NCT00125164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin, Tercica, Inc.)
Description: Twice Daily Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin, Tercica, Inc.)
Description: Twice Daily Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin, Tercica, Inc.)
Description: Twice Daily Injection
Study: NCT04238897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: soft contact lens
Study: NCT00005080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study: NCT02955849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLT laser
Description: Patients will be offered initial SLT laser by doctors
Study: NCT03212313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tozadenant
Description: Two 60 mg tablets for a total single study dose of 120 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: Two 60 mg tablets for a total single study dose of 120 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: Two 60 mg tablets for a total single study dose of 120 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: Two 60 mg tablets for a total single study dose of 120 mg
Study: NCT00996333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel, Capecitabine
Description: 1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles.
Study: NCT00636493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide (Retisert Implant)
Description: sustained release device consisting of 0.59 mg of fluocinolone acetonide
Study: NCT04717219

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood will be drawn after inclusion of the participants.
Study: NCT03365349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participating in a session of living theatre
Description: participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: writing workshop
Description: one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers.
Study: NCT04312724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Socket TF
Description: The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Socket TF
Description: The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day.
Study: NCT02506413

Intervention type: OTHER
Group type: OTHER
Intervention: MamaToto Package
Description: The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers.
Study: NCT01258686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 700mg thrice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 700mg thrice daily
Study: NCT04326803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B recombinant vaccine
Description: Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
Study: NCT03350672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
Study: NCT01911494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Description: Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
Study: NCT03614520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of olive oil
Description: 25 mL of extra virgin olive oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of red wine
Description: 150 mL or Red Wine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of red wine
Description: 150 mL or Red Wine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of red wine and olive oil
Description: 150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
Study: NCT03350672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TAF
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
Study: NCT01444040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent inject
Description: Implantation of two iStent inject devices

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: Travoprost drops
Study: NCT01795053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: playtraining
Description: playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo open play session
Study: NCT00478023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 20 mg IR; 4 - 6 hourly; Total 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 50mg; 4 - 6 hourly; Total 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 75mg; 4 -6 hourly; Total 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503 IR
Description: 100mg, 4 - 6 hourly; Total 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 - 6 hourly; Total 72 hours
Study: NCT00378365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA
Study: NCT01809340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
Study: NCT01696539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Description: Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
Study: NCT01162642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea
Description: Green Tea 4 cups daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cups placebo tea for 6 weeks
Study: NCT02377817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrenaBelt
Description: The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PrenaBelt
Description: The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham PrenaBelt
Description: The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PrenaBelt
Description: The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
Study: NCT01320917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel releasing device
Description: LNG-IUD device releases levonorgestrel in circulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cu-IUD insertion
Description: The action of a Cu-IUD does not release any hormonal compound
Study: NCT04376866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: anti-PD-1 antibody
Study: NCT02084407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination, skin biopsy, blood and urine sampling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination, skin biopsy, blood and urine sampling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination, skin biopsy, blood and urine sampling
Study: NCT03286517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Description: A neurohormone
Study: NCT05755321

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy performed during surgery.

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy performed during surgery.

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy performed during surgery.

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy performed during surgery.
Study: NCT02457143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Study: NCT01481818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
Study: NCT00264732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolimogene
Description: 1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolimogene
Description: 3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
Study: NCT02535806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: 4 doses of study drug will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal dose For CNS negative patients, Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate / Hydrocortisone / Cytarabine
Description: Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Days 1-5 and 15-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Days 3 and 17
Study: NCT01483521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical home visitation
Description: Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
Study: NCT03616028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left atrial appendage closure
Description: Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
Study: NCT01123902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand-held fan
Description: Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wristband
Description: Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.